BD completes clinical trial for its wearable injector

11 Feb 2020

The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.

BD (Becton, Dickinson and Company) has completed a 50-subject human clinical trial with the BD Libertas Wearable Injector.

BD completes clinical trial for its wearable injector
The BD Libertas Wearable Injector.

The award-winning injector (the Good Design Award and the iF Award) is a subcutaneous drug delivery system, currently in development, that is designed to require no patient assembly and deliver biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.

The BD independently sponsored and conducted study was designed to evaluate the performance of the 5 mL BD Libertas device in human subjects, including tissue effects, skin reactivity and patient acceptance. The results are expected to be announced early 2020.

The study represents the most recent in a series of over 50 BD conducted pre-clinical and clinical studies intended to measure the performance of the BD Libertas Wearable Injector, demonstrate feasibility of 2-10 mL biologic injections into subcutaneous tissue and characterize tissue response to large volume injections in human and animal subjects.

Commenting on the study, Peter Nolan, Worldwide President, BD Pharmaceutical Systems, said: “BD is committed to bringing value to our pharma partnerships, including providing them with independent BD sponsored and generated study data to accelerate combination product development. The recent study reflects BD’s continued investment in solutions to meet pharma’s needs by expanding the design space for biologics delivery.”

Read More

Related news

New blood test able to detect 50 cancer types

New blood test able to detect 50 cancer types

31 Mar 2020

Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.

Read more 
European patent granted for amatoxin conjugates for tumor therapy

European patent granted for amatoxin conjugates for tumor therapy

31 Mar 2020

The patent covers the crosslinking of certain carrier molecules, for example, antibodies, via specific binding sites to amatoxins.

Read more 
ProBioGen selected for development and large-scale manufacturing services

ProBioGen selected for development and large-scale manufacturing services

24 Mar 2020

The Contract Development and Manufacturing Organization (CDMO) and technology provider will use its CHO.RiGHT expression platform for high-titer cell line development.

Read more 
Positive update on the development of new XF‐platform drug formulations

Positive update on the development of new XF‐platform drug formulations

24 Mar 2020

Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.

Read more 
Alvotech and DKSH partner to bring key biosimilar to Asia

Alvotech and DKSH partner to bring key biosimilar to Asia

24 Mar 2020

Together, the companies will provide APAC markets with a cost-effective alternative to the largest-selling blockbuster medicine worldwide.

Read more 
Codexis and Takeda collaborate to advance novel gene therapies

Codexis and Takeda collaborate to advance novel gene therapies

23 Mar 2020

Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies.

Read more 
Vaxxas HD-MAP to deliver vaccines directly to the skin

Vaxxas HD-MAP to deliver vaccines directly to the skin

17 Mar 2020

Company awarded US$5 million grant for clinical study of measles and rubella vaccination using Vaxxas’ high-density, micro-array patch.

Read more 
Regeneron and Sanofi begin global Kevzara clinical trial program in patients with severe COVID-19

Regeneron and Sanofi begin global Kevzara clinical trial program in patients with severe COVID-19

16 Mar 2020

The trial is the first controlled trial in the US to evaluate the effect of IL-6 inhibition prospectively in COVID-19 patients.

Read more 
Technique improves drug delivery system characterization

Technique improves drug delivery system characterization

16 Mar 2020

Postnova Analytics' CF2000 Centrifugal Field Flow Fractionation (CF3) system is delivering exciting new data to scientists developing drug delivery systems.

Read more 
Nanoform and Orion collaborate on 'nanoformed' APIs

Nanoform and Orion collaborate on 'nanoformed' APIs

9 Mar 2020

Active pharmaceutical ingredients (APIs) nanoformed using the CESS process demonstrate promise for overcoming solubility and bioavailability challenges.

Read more